Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Sander W Tas

Showing results (131-140 of 141) with videos related to

Pageof 15
Sort By:
RMD Open|October 7, 2024
Methotrexate treatment hampers induction of vaccine-specific CD4 T cell responses in patients with IMIDLaura Y L Kummer, Laura Fernández Blanco, Christine Kreher, et al.
Clinical and Experimental Rheumatology|March 14, 2023
ERN ReCONNET points to consider for treating patients living with autoimmune rheumatic diseases with antiviral therapies and anti-SARS-CoV-2 antibody productsRosaria Talarico, Giuseppe Alvise Ramirez, Sofia C Barreira, et al.
Science Translational Medicine|September 18, 2024
A deep intronic splice-altering <i>AIRE</i> variant causes APECED syndrome through antisense oligonucleotide-targetable pseudoexon inclusionSebastian Ochoa, Amy P Hsu, Andrew J Oler, et al.
BMC Medicine|March 3, 2022
Risk factors associated with short-term adverse events after SARS-CoV-2 vaccination in patients with immune-mediated inflammatory diseasesLuuk Wieske, Laura Y L Kummer, Koos P J van Dam, et al.
Journal of Autoimmunity|January 9, 2023
Disease activity in patients with immune-mediated inflammatory diseases after SARS-CoV-2 vaccinationsKoos P J van Dam, Luuk Wieske, Eileen W Stalman, et al.
BMC Infectious Diseases|May 17, 2023
Primary SARS-CoV-2 infection in patients with immune-mediated inflammatory diseases: long-term humoral immune responses and effects on disease activityKoos P J van Dam, Adriaan G Volkers, Luuk Wieske, et al.
Annals of the Rheumatic Diseases|January 31, 2023
Persistence of seroconversion at 6 months following primary immunisation in patients with immune-mediated inflammatory diseasesLuuk Wieske, Eileen W Stalman, P J Koos van Dam, et al.
Annals of the Rheumatic Diseases|November 10, 2022
Breakthrough infections with the SARS-CoV-2 omicron (B.1.1.529) variant in patients with immune-mediated inflammatory diseasesEileen W Stalman, Luuk Wieske, Koos P J van Dam, et al.
The Lancet. Rheumatology|March 23, 2022
Humoral responses after second and third SARS-CoV-2 vaccination in patients with immune-mediated inflammatory disorders on immunosuppressants: a cohort studyLuuk Wieske, Koos P J van Dam, Maurice Steenhuis, et al.
The Journal of Allergy and Clinical Immunology|May 19, 2024
Clinical and humoral response after SARS-CoV-2 breakthrough infection in patients receiving immunosuppressant therapyEileen W Stalman, Luuk Wieske, Jim B D Keijser, et al.
Pageof 15

Showing results (131-140 of 141) with videos related to

Sort By:
Pageof 15
RMD Open|October 7, 2024
Methotrexate treatment hampers induction of vaccine-specific CD4 T cell responses in patients with IMIDLaura Y L Kummer, Laura Fernández Blanco, Christine Kreher, et al.
Clinical and Experimental Rheumatology|March 14, 2023
ERN ReCONNET points to consider for treating patients living with autoimmune rheumatic diseases with antiviral therapies and anti-SARS-CoV-2 antibody productsRosaria Talarico, Giuseppe Alvise Ramirez, Sofia C Barreira, et al.
Science Translational Medicine|September 18, 2024
A deep intronic splice-altering <i>AIRE</i> variant causes APECED syndrome through antisense oligonucleotide-targetable pseudoexon inclusionSebastian Ochoa, Amy P Hsu, Andrew J Oler, et al.
BMC Medicine|March 3, 2022
Risk factors associated with short-term adverse events after SARS-CoV-2 vaccination in patients with immune-mediated inflammatory diseasesLuuk Wieske, Laura Y L Kummer, Koos P J van Dam, et al.
Journal of Autoimmunity|January 9, 2023
Disease activity in patients with immune-mediated inflammatory diseases after SARS-CoV-2 vaccinationsKoos P J van Dam, Luuk Wieske, Eileen W Stalman, et al.
BMC Infectious Diseases|May 17, 2023
Primary SARS-CoV-2 infection in patients with immune-mediated inflammatory diseases: long-term humoral immune responses and effects on disease activityKoos P J van Dam, Adriaan G Volkers, Luuk Wieske, et al.
Annals of the Rheumatic Diseases|January 31, 2023
Persistence of seroconversion at 6 months following primary immunisation in patients with immune-mediated inflammatory diseasesLuuk Wieske, Eileen W Stalman, P J Koos van Dam, et al.
Annals of the Rheumatic Diseases|November 10, 2022
Breakthrough infections with the SARS-CoV-2 omicron (B.1.1.529) variant in patients with immune-mediated inflammatory diseasesEileen W Stalman, Luuk Wieske, Koos P J van Dam, et al.
The Lancet. Rheumatology|March 23, 2022
Humoral responses after second and third SARS-CoV-2 vaccination in patients with immune-mediated inflammatory disorders on immunosuppressants: a cohort studyLuuk Wieske, Koos P J van Dam, Maurice Steenhuis, et al.
The Journal of Allergy and Clinical Immunology|May 19, 2024
Clinical and humoral response after SARS-CoV-2 breakthrough infection in patients receiving immunosuppressant therapyEileen W Stalman, Luuk Wieske, Jim B D Keijser, et al.
Pageof 15